Showing results (501-510 of 700) with videos related to

Sort By:
Pageof 70
Biorxiv : the Preprint Server for Biology|December 31, 2025
NKTR-255, a polymer-conjugated IL-15, synergizes with CAR-T cell therapy to activate endogenous anti-tumor immunity and improve tumor controlW Sam Nutt, Mitchell G Kluesner, Emma Bingham, et al.
Cancer Research|June 25, 2009
Active Notch1 confers a transformed phenotype to primary human melanocytesChelsea C Pinnix, John T Lee, Zhao-Jun Liu, et al.
JCI Insight|January 19, 2017
A patient-derived-xenograft platform to study BRCA-deficient ovarian cancersErin George, Hyoung Kim, Clemens Krepler, et al.
Cell Reports. Medicine|October 8, 2021
CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer modelsHaineng Xu, Erin George, Yasuto Kinose, et al.
Developmental Cell|May 26, 2022
A human breast atlas integrating single-cell proteomics and transcriptomicsG Kenneth Gray, Carman Man-Chung Li, Jennifer M Rosenbluth, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 13, 2012
Genetic susceptibility to type 2 diabetes and breast cancer risk in women of European and African ancestryNingqi Hou, Yonglan Zheng, Eric R Gamazon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2015
Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination TherapiesClemens Krepler, Min Xiao, Katrin Sproesser, et al.
Autophagy|July 4, 2014
Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanomaReshma Rangwala, Robert Leone, Yunyoung C Chang, et al.
Population Health Management|November 20, 2020
Relationship of Clinician Care Team Composition and Diabetes Quality OutcomesBenjamin D Meyerink, Michelle A Lampman, Susan B Laabs, et al.
Cancer Cell|December 16, 2010
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3KJessie Villanueva, Adina Vultur, John T Lee, et al.
Pageof 70